Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 1

Treating oligohydramnios with extract of Salvia miltiorrhiza: A randomized control trial

Authors Chu H, Shen M

Published 8 February 2008 Volume 2008:4(1) Pages 287—290

DOI https://doi.org/10.2147/TCRM.S2527

Hong-nü Chu, Mei-juan Shen

Affiliated Hospital, School of Medicine, Hangzhou Normal University, 310016, Hangzhou, China

Objective: To determine whether purified herbal extract of Salvia miltiorrhiza can improve the amniotic fluid volume in pre-term oligohydramnios by improving uteroplacental circulation.

Methods: Forty-three pregnant women with oligohydramnios received a daily intravenous dose of 30 mL of salvia extract mixed with 5% glucose 500 mL. A control group of 41 women received daily 5% glucose 500 mL only. The amniotic fluid index (AFI) was assessed at least twice a week by ultrasonographists who were blinded to the treatment. Both women and fetuses were monitored closely. The change in AFI was calculated and compared by paired t test within and between groups. The revised recommendations for improving the quality of reports of parallel group randomized trials were used.

Results: After a mean of 7.2 ± 2.7 days’ therapy, ranging from 3 to 18 days, the AFI increased significantly from a mean of 4.9 ± 2.3 cm to a mean of 7.12 ± 2.36 cm, by a mean of AFI 0.18 ± 0.06 cm/day (paired t = 3.62, p < 0.005). In the control group, the AFI increased from a mean of 5.1 ± 2.4 cm to a mean of 5.5 ± 3.1 cm after a mean of 6.1 ± 3.3 days’ treatment, ranging from 4 to 15 days. The effect of salvia treatment on AFI in the salvia group was significantly greater than in the control group (p < 0.001). No side effects were observed in treated patients.

Conclusion: Salvia miltiorrhiza is an effective Chinese medicine for the treatment of oligohydramnios.

Keywords: Salvia miltiorrhiza, therapy, oligohydramnios, amniotic fluid index

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

A review of topotecan in combination chemotherapy for advanced cervical cancer

Minoo Robati, David Holtz, Charles J Dunton

Therapeutics and Clinical Risk Management 2008, 4:213-218

Published Date: 8 February 2008

Editorial ||FREE PAPER||

Garry M Walsh

Therapeutics and Clinical Risk Management 2008, 4:0-0

Published Date: 8 February 2008

Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review

Jason W Bennett, James S Lewis II, Michael W Ellis

Therapeutics and Clinical Risk Management 2008, 4:31-40

Published Date: 8 February 2008

Trabectedin and its potential in the treatment of soft tissue sarcoma

Philippe A Cassier, Armelle Dufresne, Jean-Yves Blay, Jérôme Fayette

Therapeutics and Clinical Risk Management 2008, 4:109-116

Published Date: 8 February 2008

Management of laryngopharyngeal reflux with proton pump inhibitors

Christina Reimer, Peter Bytzer

Therapeutics and Clinical Risk Management 2008, 4:225-233

Published Date: 8 February 2008

A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)

Lala M Dunbar, Derek M Tang, Robert M Manausa

Therapeutics and Clinical Risk Management 2008, 4:235-244

Published Date: 8 February 2008

Factors affecting therapeutic compliance: A review from the patient’s perspective

Jing Jin, Grant Edward Sklar, Vernon Min Sen Oh, Shu Chuen Li

Therapeutics and Clinical Risk Management 2008, 4:269-286

Published Date: 8 February 2008

Cannabinoids in the management of difficult to treat pain

Ethan B Russo

Therapeutics and Clinical Risk Management 2008, 4:245-259

Published Date: 8 February 2008